Delving into the Latest Updates on Abrocitinib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ABRO, PF 04965842, PF-04965842

+ [5]

Target

JAK1

Action

inhibitors

Mechanism

JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors)

Therapeutic Areas

Immune System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases+ [5]

Active Indication

Dermatitis, AtopicEczemaModerate Atopic Dermatitis+ [6]

Inactive Indication

Liver InjuryPlaque psoriasisprurigo nodularis+ [1]

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Inc.Pfizer Europe MA EEIGPfizer Canada ULC

+ [3]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United Kingdom (08 Sep 2021),

Dermatitis, Atopic

RegulationPriority Review (United States), Breakthrough Therapy (United States), Priority Review (China), Promising Innovative Medicine (United Kingdom)

Login to view timeline

Structure/Sequence

Molecular FormulaC14H21N5O2S

InChIKeyIUEWXNHSKRWHDY-PHIMTYICSA-N

CAS Registry1622902-68-4

The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:
What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?
What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?
Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.

Start Date01 May 2026

Sponsor / Collaborator-

NCT06899204

/ RecruitingNot Applicable

A Prospective, Multi-center Observational Study Characterizing Clinical Outcomes of Patients Receiving Abrocitinib for Moderate-to-severe Atopic Dermatitis Who Had an Inadequate Response (or Intolerance) to ≤2 Previous Biologic Therapies Approved for Moderate-to-severe Atopic Dermatitis

This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or intolerance) to ≤2 previous biologic therapies approved for M2S AD in the United States.
The aim of this study is to measure the effectiveness of abrocitinib in a real-world setting in patients with moderate-to-severe atopic dermatitis, with inadequate response or intolerance to ≤2 biologic therapies.

Start Date13 Jan 2026

Sponsor / Collaborator

Pfizer Inc.

NCT07242638

/ RecruitingPhase 2IIT

Use of Specific JAK Inhibition on Inflammatory Skin and Scalp Diseases in Down Syndrome R61AR084210

This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks. Responders (defined as achieving Eczema Area and Severity Index (EASI) 75 response for AD, or SALT <= 20 for AA) will be kept on this dose, and non-responders based on these definitions, will initiate 200 mg daily for another 12 weeks. All AD and AA patients will be maintained on the respective dose of Abrocitinib from Week 24 through week 60.

Start Date12 Jan 2026

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

100 Clinical Results associated with Abrocitinib

Login to view more data

100 Translational Medicine associated with Abrocitinib

Login to view more data

100 Patents (Medical) associated with Abrocitinib

Login to view more data

479

Literatures (Medical) associated with Abrocitinib

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort

Article

Author: Ulutaş Demirbaş, Gözde ; Esen, Mustafa ; Diremsizoglu, Esin ; Demirbaş, Abdullah

BACKGROUND:

Dose-stratified real-world data for JAK1 inhibitors in AD are limited.

OBJECTIVE:

To compare effectiveness and safety of standard vs high doses of abrocitinib and upadacitinib in routine care.

METHODS:

Multicenter, retrospective cohort study. The primary endpoint was Week-12 achievement of Eczema Area and Severity Index (EASI)-75. Secondary outcomes included patient-reported improvements at Minimal Clinically Important Difference (MCID) thresholds, Minimal Disease Activity (MDA) at Week 36, time-to-EASI-75, and treatment-emergent adverse events(TEAE).

RESULTS:

A total of 124 patients were analyzed (abrocitinib 100 mg, n = 28; abrocitinib 200 mg, n = 32; upadacitinib 15 mg, n = 30; upadacitinib 30 mg, n = 34). At Week 12, EASI-75 was achieved in 20/32 (62.5%) versus 10/28 (35.7%) for abrocitinib (OR 2.94, 95% CI 1.06-8.15; p = 0.036) and in 22/34 (64.7%) versus 14/30 (46.7%) for upadacitinib (OR 2.92, 95% CI 1.16-7.38; p = 0.021), favoring the higher-dose regimens. Itch improvement was more frequent with higher doses. By Week 36, full minimal disease activity was observed in 30.2% of patients receiving abrocitinib 200 mg and 26.7% receiving upadacitinib 30 mg, compared with 18.4% and 20.0% in the lower-dose groups. Kaplan-Meier analysis showed faster responses with high doses (median 12 vs 36 weeks; log-rank p < 0.01). Safety was comparable across groups.

CONCLUSION:

High-dose JAK1 regimens achieve faster, numerically greater disease control without short-term safety tradeoffs, supporting escalation in suboptimal responders.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Cost-utility and budget impact analysis of dupilumab and oral Janus kinase (JAK) inhibitors for treating moderate-to-severe atopic dermatitis in Taiwan

Article

Author: Lee, John Tayu ; Wu, David Bin-Chia ; Shen, Toby Kai-Bo ; Yang, Rachel Ai-Ting ; Tan, Hsiao-Hsiao ; Liu, Valerie Tzu-Ning ; Wang, Yen Hsiang

BACKGOROUND:

Atopic dermatitis (AD), a chronic inflammatory skin disease, affects 1.28% of Taiwan's population, with 26.69% having moderate-to-severe cases, causing significant healthcare costs and quality-of-life impairments. Conventional treatments often fail these patients, necessitating novel therapies like dupilumab and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib). This study evaluates the cost-utility and budget impact of these therapies versus best supportive care (BSC) for adults with moderate-to-severe AD from Taiwan's NHI perspective.

METHODS:

A hybrid decision tree-Markov model assessed short- and long-term (Years 1-20) outcomes using trial efficacy, NHI costs (2022 NT$), and EQ-5D utilities. Interventions included topical corticosteroids/calcineurin inhibitors. Outcomes were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs), discounted at 3%, with a NT$2,000,000/QALY threshold. Sensitivity analyses tested robustness. A five-year (2026-2030) budget impact analysis (BIA) included epidemiology and market uptake.

RESULTS:

Upadacitinib 30 mg was most cost-effective (11.0782 QALYs, ICER NT$1,250,903/QALY vs BSC), followed by Upadacitinib 15 mg (NT$1,376,435/QALY). Dupilumab was dominated; Baricitinib's ICERs exceeded NT$2,000,000/QALY. Sensitivity analyses confirmed robustness, with utility gains, medication costs, and discontinuation rates as key drivers. The BIA estimated a NT$117 billion incremental impact, driven by drug costs, with per-patient increments falling from NT$339,769 to NT$264,728.

CONCLUSION:

Upadacitinib 30 mg was the most cost-effective option for moderate-to-severe atopic dermatitis in Taiwan, but its high budget impact underscores the need for strategic pricing and reimbursement policies to ensure long-term affordability and access.

02 Mar 2026·Dermatitis

Decision-Making Factors for Systemic Therapies in Atopic Dermatitis: A Clinical Review.

Review

Author: Mehta, Apoorva ; Guttman-Yassky, Emma ; O'Hagan, Ross ; Lamb, Angela J ; Levine, Jasmine

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impairs quality of life. In recent years, treatment has advanced from broad immunosuppressants to targeted biologics and small-molecule therapies that modulate type 2 inflammation and itch signaling. Dupilumab, tralokinumab, lebrikizumab, and nemolizumab are now FDA-approved biologics with demonstrated efficacy and favorable long-term safety, while oral Janus kinase inhibitors (JAKis) such as abrocitinib, upadacitinib, and baricitinib often provide rapid disease control but carry black-box warnings. Comparative trials highlight faster itch relief with JAKis but durable disease control and safety advantages with biologics. The expanding treatment landscape necessitates individualized therapy selection. Key clinical considerations include patient age, pregnancy status, infection, malignancy, or thromboembolic risk, comorbid conditions, and history of adverse effects. Equally important are patient-centered preferences such as dosing frequency, route of administration, storage logistics, and willingness to self-inject. Access and affordability also influence care, with many manufacturers offering copay support and patient assistance programs. Future directions emphasize head-to-head comparative studies, biomarker development for precision treatment, and equitable access to advanced therapies. This narrative review synthesizes current evidence on biologics and JAKis in AD, outlining efficacy, safety, and practical decision-making factors to guide dermatologists in aligning therapies with both clinical context and patient priorities.

58

News (Medical) associated with Abrocitinib

09 Mar 2026
·allsci.com

Harbour Bio, Kelun’s bispecific TSLP antibody to enter clinic in China for atopic dermatitis

Harbour BioMed (HBM; HKEX: 02142) and Kelun-Biotech (6990.HK) announced that China’s National Medical Products Administration (NMPA) has approved an Investigational New Drug (IND) application for HBM7575/SKB575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed second antigen, for the treatment of atopic dermatitis. The IND clearance permits the companies to initiate clinical trials in China. The IND approval authorizes first-in-human or early-phase clinical studies of HBM7575/SKB575 in patients with atopic dermatitis. Under a co-development deal between Kelun and HBM, Kelun is leading the design, development, and commercialization of HBM7575/SKB575 globally. The molecule is engineered for subcutaneous administration, and preclinical half-life data suggest a dosing interval exceeding three months, the companies said. The drug candidate’s mechanism involves dual antagonism: blocking TSLP from binding its receptor to inhibit Th2 cell activation, and simultaneously binding an undisclosed target to generate what the companies describe as a synergistic effect intended to overcome resistance associated with single-target anti-TSLP antibodies. Atopic dermatitis affects approximately 20% of children and up to 10% of adults globally, according to the Atopic Dermatitis Atlas. Current treatments include topical corticosteroids, biologics such as dupilumab (Dupixent, Regeneron/Sanofi) and tralokinumab (Adbry, LEO Pharma), JAK inhibitors including upadacitinib (Rinvoq, AbbVie) and abrocitinib (Cibinqo, Pfizer), and more recently approved agents such as nemolizumab (Nemluvio, Galderma) and lebrikizumab (Ebglyss, Eli Lilly). Despite this expanding armamentarium, many patients with moderate-to-severe disease do not achieve sustained control, and the cyclical nature of flare-ups and remissions continues to represent a treatment gap. HBM7575/SKB575 joins a competitive landscape that includes several agents in late-stage development targeting pathways beyond IL-4/IL-13, including amlitelimab (anti-OX40L, Sanofi, Phase III), rocatinlimab (anti-OX40, Amgen, Phase 3), and tezepelumab (anti-TSLP, Amgen/AstraZeneca, Phase II in atopic dermatitis). TSLP-directed therapy has been validated in asthma through tezepelumab’s approval as Tezspire, but no anti-TSLP agent has yet been approved for atopic dermatitis. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 2INDPhase 3

04 Mar 2026
·allsci.com

Kyowa Kirin and Amgen terminate OX40 rocatinlimab trials after malignancy signal

Japan-based Kyowa Kirin Co., Ltd and partner Amgen announced the discontinuation of all ongoing clinical trialsof rocatinlimab, an anti-OX40 monoclonal antibody that had reached late-stage development for moderate-to-severe atopic dermatitis, prurigo nodularis, and asthma. The companies announced the decision following a safety review that identified emerging malignancy cases with possible viral or immune-related links, including Kaposi’s sarcoma. According to the companies, the review identified one newly confirmed case and one suspected case of Kaposi’s sarcoma in addition to a previously confirmed case. While the overall number of malignancies observed across the clinical program remained below expected background incidence, the characteristics of the cases raised concerns that a biologically plausible risk could not be excluded. Kyowa Kirin and Amgen concluded that the potential safety risk may outweigh the benefits for patients in the studied indications. Rocatinlimab, previously designated AMG 451 by Amgen and KHK4083 by Kyowa Kirin, was designed as a fully human, non-fucosylated IgG1 antibody targeting the OX40 receptor on activated T cells. The molecule’s engineered Fc region enhances antibody-dependent cellular cytotoxicity (ADCC), enabling depletion of OX40-expressing pathogenic T cells in addition to blocking OX40 signaling. The therapeutic strategy aimed to rebalance immune responses in Th2-driven diseases such as atopic dermatitis, potentially delivering durable disease modification rather than temporary suppression of inflammatory cytokines. Phase III program halted despite positive efficacy results The decision halts the global ROCKET Phase III program, which comprised eight studies across multiple indications and geographic regions. Two pivotal atopic dermatitis trials had already reported positive top-line results before the safety signal emerged. The ROCKET HORIZON study (NCT05651711) met both co-primary endpoints—vIGA-AD 0/1 with at least a two-point reduction and EASI-75 at Week 24—as well as key secondary endpoints at the 300 mg subcutaneous dose. The ROCKET IGNITE trial (NCT05398445) also achieved its co-primary endpoints. Additional Phase III trials included (ROCKET BOOST) evaluating rocatinlimab with topical corticosteroids, ROCKET LAUNCH assessing alternative dosing regimens, an adolescent open-label study, and a long-term extension trial. Parallel development programs were underway in prurigo nodularis and asthma, all of which have now been terminated. Mechanistic concerns tied to viral-associated malignancy Kaposi’s sarcoma is caused by human herpesvirus-8 (HHV-8) and typically arises in settings of impaired immune surveillance. Because rocatinlimab was designed to deplete activated T cells through enhanced ADCC, the companies concluded that interference with antiviral immune responses represents a plausible mechanistic explanation for the observed signal. Neither company disclosed detailed safety datasets beyond the malignancy cases noted in the announcement. Both said they are notifying investigators and regulators and will conduct further analysis of the full clinical dataset. Development history Rocatinlimab’s development began with an early Phase I study in Japanese patients with atopic dermatitis around 2015. Subsequent Phase II studies—including a Phase IIb trial in atopic dermatitis initiated in 2018—demonstrated clinical efficacy and generated interest after data presented at the EADV Congress in 2021 suggested durable improvement after treatment cessation. In June 2021, Amgen and Kyowa Kirin entered a global collaboration agreement under which Amgen assumed sponsorship of the Phase III program while both companies retained commercialization rights. Kyowa Kirin said it will retain control of the rocatinlimab program, including regulatory filings and future commercialization decisions, although no development path has been outlined following the trial terminations. Implications for the OX40 pathway The discontinuation removes the most advanced OX40-targeted therapy from clinical development in inflammatory disease. The atopic dermatitis treatment landscape is already dominated by cytokine-targeted therapies such as dupilumab, tralokinumab, and lebrikizumab, alongside JAK inhibitors including abrocitinib and upadacitinib. Rocatinlimab had been differentiated by its upstream mechanism—targeting pathogenic T cells rather than individual cytokines. Its termination leaves no OX40-targeted therapy in late-stage development for inflammatory indications. Early-stage oncology programs involving OX40 agonists, designed to stimulate T-cell responses rather than suppress them, remain in development and are not directly affected by the findings. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 2Phase 3Phase 1Clinical ResultImmunotherapy

19 Nov 2024
·pharma.economictimes.indiatimes.com

Glenmark to focus on becoming branded company, says Glenn Saldanha

Mumbai: Glenmark is focusing on moving up the value chain to transform into a branded pharmaceutical company with a significant portion of its revenue coming from higher-margin branded products, having overcome a challenging period, its chairman and managing director Glenn Saldanha told ET. “I think we've come a long way… We had three, four difficult years,” he said, citing issues with the US Food and Drug Administration (FDA), the Department of Justice (DOJ) and some litigations. “Lots of challenges we faced… All that is behind us,” Saldanha added. “I think now things are much better. So, the platform is set to continue to scale and to grow faster.” On some analysts raising doubts about Glenmark’s way forward after the sale of Glenmark Life Sciences (GLS), its active pharmaceutical ingredient business, and some branded portfolios, Saldanha said, “We've done some portfolio rationalisation, and the GLS divestment was because our view was, given the changing dynamic in the generics business, we didn't find the need to keep the API business within our portfolio. The sale helped us to re-channelise our entire energies into becoming a branded company.” He said the “aggression and the passion” are intact and the company isn't going to slow down. “We will not give up (on) scale.” Glenmark has been cleaning up its balance sheet. It used the proceeds from GLS divestment to pare debt. It currently has a debt-to-equity ratio of 0.16%. The company halved its expenditure on R&D from $120-130 million per annum at its peak to about $60 million through a series of out-licensing deals. Saldanha said the company will record Rs 13,500-14,000 crore of revenues this year, growing at about 12%-15% CAGR, and reach about Rs 15,500 crore next year. Almost 65% of its revenues are coming from branded business, which gives the business stability from pricing pressures, he said. Glenmark ended FY24 with revenue of around Rs 10,944 crore in revenue with an Ebitda margin of 19%. India contributes one-third of its revenue, while the US accounts for 28% and Europe 12%. Saldanha said the company will increasingly focus on three therapeutic segments – respiratory, dermatology and oncology – for its branded business. In early January, Glenmark became the first Indian company to launch a biosimilar of anti-diabetic GLP-1 drug Liraglutide in the country. It has also announced a series of partnerships to bring innovative drugs including tie-ups with Jiangsu Alphamab Biopharmaceuticals and 3D Medicines for KN035 (Envafolimab) for multiple geographies around the world. It partnered with Pfizer to launch Abrocitinib, used for treating atopic dermatitis in India under the brand name Jabryus. It has entered into an agreement with BeiGene for marketing and distribution of Tislelizumab and Zanubrutinib in India. By Viswanath Pilla ,

AcquisitionLicense out/inDrug Approval

100 Deals associated with Abrocitinib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11400	Abrocitinib	D11AH	DB14973

R&D Status

Approved

10 top approved records.
Login
to view more data

Indication	Country/Location	Organization	Date
Dermatitis, Atopic	United Kingdom	Pfizer Inc.	08 Sep 2021

Developing

10 top R&D records.
Login
to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Eczema	Phase 3	United States	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	China	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Argentina	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Belgium	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Brazil	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Bulgaria	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Canada	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Chile	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Germany	Pfizer Inc.	11 Jun 2018
Eczema	Phase 3	Israel	Pfizer Inc.	11 Jun 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03575871 \| NCT03422822 \| NCT03349060 \| NCT03796676 \| NCT03627767 (JADE MONO-1, MONO-2, TEEN, REGIMEN, EXTEND, Pubmed \| Allergy)	Phase 3	Moderate Atopic Dermatitis	-	Abrocitinib 200mg	mvstqqaafz(fzgzxsjhjr) = esfdgpzkap xfgyhjzkic (jupftiqgcw ) View more	Positive	01 Aug 2025
				Abrocitinib 100mg	mvstqqaafz(fzgzxsjhjr) = qvpmmqfsyr xfgyhjzkic (jupftiqgcw ) View more
AHEAD (NEWS) Manual	Not Applicable	Dermatitis, Atopic	-	阿布昔替尼 (未接受过其他系统治疗)	oopgymwycq(cxjvgrrbxi) = bevxuxqhhh exkjnzrmsl (latpyiatcz )	Positive	27 Jun 2025
				阿布昔替尼 (既往接受过系统治疗)	oopgymwycq(cxjvgrrbxi) = bjysrmucvg exkjnzrmsl (latpyiatcz )
ChiCTR2200063195 (Pubmed) Manual	Not Applicable	Dermatitis, Atopic	117	Abrocitinib	pbrqzlbsky(lyxbgscets) = mqicgbsodx mtablffkyn (ofbbhxabit ) View more	Positive	01 May 2025
AAD2025	Not Applicable	Severe Atopic Dermatitis	530	Upadacitinib	spofmkcpqr(xaigitkneu) = lsbgxrpivv cvjvjbaagp (ucykqbybsq ) View more	Positive	07 Mar 2025
				Baricitinib	spofmkcpqr(xaigitkneu) = ulesimicmx cvjvjbaagp (ucykqbybsq ) View more
NCT03349060 (JADE MONO-1, AAD2025)	Phase 3	Dermatitis, Atopic	2,082	Abrocitinib 100 mg	crcydijnwb(mamydkzdnr) = ecmggomnfj ujogkktplw (yvwrcjskfh ) View more	Positive	07 Mar 2025
				Abrocitinib 200 mg	dfqyxoskxy(bhyccaklpj) = knclethwwj kecauvnkbn (naikorklaw ) View more
AAD2025	Not Applicable	Dermatitis, Atopic	123	tralokinumab	npmdavtbyi(rdktuiigxz) = pkfgtncgjx kytenxbdau (dmqbrhyvgh ) View more	Positive	07 Mar 2025
				abrocitinib	npmdavtbyi(rdktuiigxz) = fgeduoxejn kytenxbdau (dmqbrhyvgh ) View more
NCT03349060 (JADE MONO-1, AAD2025)	Phase 3	Dermatitis, Atopic	-	Abrocitinib 200 mg	rnyogptqev(cobnssfxxw) = kajmekajyg qnkxufnenm (qewzyqnzyt ) View more	Positive	07 Mar 2025
				Abrocitinib 100 mg	rnyogptqev(cobnssfxxw) = lpaqwzoztz qnkxufnenm (qewzyqnzyt ) View more
NCT03422822 (JADE EXTEND, AAD2025)	Phase 3	Alopecia Areata \| Dermatitis, Atopic	71	Abrocitinib 200 mg	xvjhjqwscy(oorcjdighu) = 2 patients (31-year-old White male [previously reported] and 38-year-old White male) treated with consistent-dose abrocitinib 200 mg and 2 patients (42- and 49-year-old White males) in the variable-dose cohort reported an AE of hair growth/regrowth. Greater proportions of patients treated with consistent-dose abrocitinib 200 mg versus 100 mg achieved Week 12 IGA 0/1 (44% [11/25] vs 25% [3/12]), EASI-75 (61% [19/31] vs 25% [3/12]), and PP-NRS4 (56% [15/27] vs 22% [2/9]). Abrocitinib improved itch and skin clearance in substantial proportions of patients with AD and comorbid AA; hair growth/regrowth was reported in 4 patients. pfszduhcbc (yrvolxuhpj )	Positive	07 Mar 2025
				Abrocitinib 100 mg
NCT04345367 (JADE DARE, AAD2025)	Phase 3	Moderate Atopic Dermatitis	727	Abrocitinib 200 mg	ryoswhhgtt(otkpwioakh) = tjzsgdhioa yyawwzqhhb (gomeslngpu, 0.5 - 0.9)	Positive	07 Mar 2025
				Dupilumab 300 mg	ryoswhhgtt(otkpwioakh) = doiedlwryy yyawwzqhhb (gomeslngpu, 0.2 - 0.7)
NCT05375929 (CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	200	Abrocitinib (Main Study: Abrocitinib 200 mg)	xhrzlgrkwo = ayoiucxczn slwjonhltz (aznnhwwmth, xzekaasgvt - jntzryubcl) View more	-	19 Sep 2024
				Abrocitinib (Main Study: Abrocitinib 100 mg)	xhrzlgrkwo = jeplctunee slwjonhltz (aznnhwwmth, zheigaoguu - gmjbghkrmg) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Deal

Boost your decision using our deal data.

login

or

view full example data

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Abrocitinib

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation